Clinically effective HIV-1 protease inhibitors
- 31 July 1997
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 2 (7), 261-272
- https://doi.org/10.1016/s1359-6446(97)01053-2
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)AIDS, 1996
- In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agentsAntiviral Research, 1996
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Reduction Of The In Vitro Activity Of A77003, An Inhibitor Of Human Immunodeficiency Virus Protease, By Human Serum 1 Acid GlycoproteinThe Journal of Infectious Diseases, 1995
- Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzymeJournal of the American Chemical Society, 1995
- Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl designJournal of Medicinal Chemistry, 1992
- L-687,908, a potent hydroxyethylene containing HIV protease inhibitorJournal of Medicinal Chemistry, 1991
- Design, Activity, and 2.8 Å Crystal Structure of a C 2 Symmetric Inhibitor Complexed to HIV-1 ProteaseScience, 1990
- Rational Design of Peptide-Based HIV Proteinase InhibitorsScience, 1990
- Complete nucleotide sequence of the AIDS virus, HTLV-IIINature, 1985